Cite
Bushnell DL, Madsen MT, O'cdorisio T, et al. Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res. 2014;4(1):38doi: 10.1186/s13550-014-0038-2.
Bushnell, D. L., Madsen, M. T., O'cdorisio, T., Menda, Y., Muzahir, S., Ryan, R., & O'dorisio, M. S. (2014). Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI research, 4(1), 38. https://doi.org/10.1186/s13550-014-0038-2
Bushnell, David L, et al. "Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors." EJNMMI research vol. 4,1 (2014): 38. doi: https://doi.org/10.1186/s13550-014-0038-2
Bushnell DL, Madsen MT, O'cdorisio T, Menda Y, Muzahir S, Ryan R, O'dorisio MS. Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res. 2014 Dec;4(1):38. doi: 10.1186/s13550-014-0038-2. Epub 2014 Sep 10. PMID: 26116109; PMCID: PMC4452658.
Copy
Download .nbib